ArticleJournal of neuro-oncology2025
Neoadjuvant gamma knife surgery for metastatic brain tumor: clinical use and impact on leptomeningeal seeding.
Article in Journal of neuro-oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Local control and leptomeningeal disease after resection and GammaTile brachytherapy for newly diagnosed brain metastases: results from a prospective registry.Journal of neuro-oncology · 2026Observational
- Comment on: "Neoadjuvant gamma knife surgery for metastatic brain tumor: clinical use and impact on leptomeningeal seeding".Journal of neuro-oncology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
purposeThis study aimed to compare leptomeningeal seeding (LMS) incidence, local failure rates, and survival outcomes between neoadjuvant and adjuvant gamma knife surgery (GKS) in patients with brain metastases.
methodsWe retrospectively analyzed 120 patients treated at a single institution from 2008 to 2022. Overall survival (OS), progression‑free survival (PFS), LMS occurrence, local failure, and key clinical prognostic variables were compared between the neoadjuvant and adjuvant GKS groups.
resultsSeventy patients received neoadjuvant GKS, while 50 received adjuvant GKS. Baseline differences in primary tumor origin, preoperative Karnofsky Performance Score, and extracranial metastasis were statistically significant. No significant differences were observed in OS (p = 0.21), PFS (p = 0.27), radiation induced edema (p = 0.219) or local failure (p = 0.19) between groups. LMS incidence was significantly lower in the neoadjuvant group (p = 0.043), with this advantage maintained after propensity score matching (p = 0.046).
conclusionsNeoadjuvant GKS yields survival and local failure outcomes comparable to adjuvant GKS, while significantly reducing the risk of LMS. These findings support the potential clinical advantage of neoadjuvant GKS in the management of brain metastases.
Indexed as
Identifiers
41313358What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.